Objective: To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT / TMZ) by extending TMZ beyond 6 cycles.
Glioblastoma is an intrinsic brain tumor with an annual incidence of 3 per 100,000 individuals worldwide. Patients eligible for multimodality treatment commonly have biopsy or resection as feasible and then postoperative radiotherapy (RT) plus concomitant and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT / TMZ). [1] [2] [3] At a population level, median overall survival (OS) has markedly improved from the pre-TMZ to the TMZ era. 4 A few smaller, single-institution, retrospective studies claimed prolonged survival of patients with glioblastoma who received extended TMZ treatment beyond 6 cycles. [5] [6] [7] [8] The major limitation of all these studies, beyond the retrospective nature, is the comparison of patients who were treated with at least 7 cycles of TMZ to patients who received #6 cycles and therefore to patients who in most cases stopped TMZ because of tumor progression. Long-term administration of TMZ was associated with an acceptable safety profile in patients diagnosed with World Health Organization grade III and IV gliomas who received long-term TMZ treatment for at least 12 cycles. 9 Preliminary data from a large pooled analysis of 4 clinical trials (EORTC26981-NCIC CE.3, Radiation Therapy Oncology Group 0525, EORTC26071-CENTRIC, CORE) 3, [10] [11] [12] indicate that extended treatment with TMZ beyond 6 cycles is not associated with improved OS but with improved progression-free survival (PFS) (hazard ratio [HR] 0.8, 95% confidence interval [CI] 0.6-1) compared to patients who received exactly 6 cycles of TMZ, especially in patients with O 6 -methylguanine DNA methyltransferase (MGMT) promoter-methylated tumors (HR 5 0.6, 95% CI 0.5-0.9). 13 Here, we performed a similar analysis in patients enrolled in the German Glioma Network (GGN), a prospective cohort study, with a focus on the role of MGMT promoter methylation status and extent of residual disease after 6 cycles of adjuvant TMZ.
METHODS Standard protocol approvals, registrations, and patient consents. The GGN is a prospective cohort study involving 8 clinical centers at university hospitals in Germany that included 2,002 patients diagnosed with glioblastoma from October 2004 to October 2010 (http://www.gliomnetzwerk.de). Informed consent was signed by all patients. This study was approved by the review committees of the participating centers.
The primary research question of the present study was to explore a survival benefit from extending maintenance TMZ chemotherapy beyond 6 cycles in patients with newly diagnosed glioblastoma who received TMZ/RT / TMZ. The study is rated Class III because of the absence of randomization and because of differences in baseline characteristics of treatment groups.
This manuscript was prepared in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. 14 Patients and tumors. The present study evaluated clinical features and survival data in patients with newly diagnosed glioblastoma who received TMZ/RT / TMZ (n 5 142) with at least 6 cycles of maintenance chemotherapy without progression. The number of cycles was left to the discretion of the sites, and no recommendation was made as part of the GGN cohort study. Diagnosis of glioblastoma was confirmed according to the World Health Organization classification of tumors of the CNS 15 by central pathology review, and clinical data were collected as described. 16 The methylation status of the MGMT gene promoter region was assessed by methylation-specific PCR. 17 Analyses for isocitrate dehydrogenase (IDH) 1 or IDH2 gene mutations were performed by DNA pyrosequencing, 18 or by immunohistochemistry for IDH1-R132H protein. Formaldehyde-fixed paraffin-embedded sections 4 mm thick were cut from the tumors. After deparaffinization and antigen retrieval, mutated IDH1-R132H protein was detected by the murine monoclonal mutation-specific antibody clone H09 (Dianova, Hamburg, Germany) with the ultraView Universal DAB detection kit and a Benchmark XT immunostaining system (Ventana-Roche, Mannheim, Germany). Extent of resection was determined by early (,72 hours) postoperative imaging by MRI or by CT when MRI was not feasible or not available. Treatment decisions were made by the treating physicians, patients, and their families, commonly without awareness of the MGMT promoter methylation status; 35 patients were included in previous publications. 16, [19] [20] [21] [22] [23] [24] [25] MRI scans or at least written reports were collected at the time point when 6 cycles of TMZ chemotherapy were completed to assess tumor status. MRI scans of 36 patients were available for central radiology assessment (P.K., M.B.) according to Response Assessment in Neuro-Oncology criteria. Written neuroradiology reports were provided from 51 additional patients. Data on residual tumor were available from a total of 87 patients. Residual tumor was defined by contrast-enhancing lesions.
To avoid bias that occurs when groups to be compared are determined during study follow-up, all patients who had died or had progressive disease before completion of 6 cycles TMZ were excluded.
Statistics. PFS and OS curves were generated with the KaplanMeier method and compared by the log-rank test. PFS was calculated from the day of surgery until progression, death, or end of follow-up. OS was measured from the day of surgery to the date of death or end of follow-up. At the time of last follow-up, all patients who had not died were censored. The x 2 and Fisher exact tests were performed for analysis of nominal variables, and the Student t test was performed for quantitative variables. Cox proportional hazards regression models were used for univariate and multivariate analyses to test the association of clinical factors, residual tumor burden after 6 cycles of maintenance TMZ, and IDH mutation status and MGMT promoter methylation status with outcome. For the multivariate model, patients who had complete information on all tested covariables were included (age, extent of resection, Karnofsky performance score [KPS] at the time of diagnosis, MGMT promoter methylation status, IDH mutation status, residual tumor after 6 cycles of maintenance TMZ). A landmark analysis with a 7-month landmark was performed to estimate landmark PFS and landmark OS after the end of the 6 cycles of maintenance TMZ. All statistical tests were 2 tailed. A value of p 5 0.05 was defined as statistically significant. All statistical analyses were performed with IBM (Armonk, NY) SPSS Statistics version 24.0.
RESULTS Patient characteristics. The principal patient characteristics are summarized in table 1 and table e-1 at Neurology.org. A total of 142 patients with newly diagnosed glioblastoma were identified in the GGN database (figure e-1). Patients were divided into 2 groups defined by the number of TMZ cycles: 6 cycles (group A, n 5 81) and $7 cycles (group B, n 5 61). The median number of TMZ cycles in group B was 11 (range 7-20). figure 1B) . Absence vs presence of residual tumor after 6 cycles of maintenance TMZ was strongly prognostic (PFS p , 0.001; OS p , 0.001) (figure e-2B). However, extended TMZ treatment beyond 6 cycles was not figure  1, C and D) . The apparent plateau in group B in patients without residual tumor results from a larger number of long-term surviving patients with IDHmutant glioblastomas. For patients without tumor burden after 6 cycles of TMZ and with OS .48 months, IDH mutations were observed in 5 of 9 patients in group B and in 2 of 11 patients in group A.
In addition, a 7-month landmark analysis was performed to estimate PFS and OS after the end of the 6 cycles of maintenance TMZ ( figure e-3 Association of age, sex, extent of resection, KPS, MGMT promoter methylation status, IDH mutation status, residual tumor, and TMZ cycles with outcome. Patients were divided into 2 groups defined by age, sex, extent of resection, KPS, MGMT promoter methylation status, IDH mutation status, residual tumor, and TMZ cycles. Univariate analysis using the Cox proportional hazard model was performed to assess their association with PFS or OS. Extent of resection, MGMT promoter methylation status, IDH mutation status, and residual tumor burden after 6 cycles of maintenance TMZ, but not age, sex, KPS, or extended TMZ treatment, were risk factors for progression. In addition, age, extent of resection, MGMT promoter methylation status, IDH mutation status, and residual tumor after 6 cycles of maintenance TMZ, but not, sex, KPS, or extended TMZ treatment, were identified as significant risk factors for survival (table 3) .
Multivariate analysis was performed to address whether extended TMZ treatment might be an independent factor associated with survival when adjusted that defined the 6 cycles somewhat arbitrarily. 26 Accordingly, numerous efforts of improving outcome by intensifying adjuvant TMZ have been undertaken, using dose intensification in the first 6 months, prolongation of TMZ maintenance, or both, 12, 27, 28 all without convincing results to suggest superiority compared with the standard of 6 cycles at 5 of 28 days. Yet, prolonging TMZ maintenance beyond 6 to 12 months or even more has become a common practice, notably in the United States.
Here, we used the GGN cohort to identify 142 patients who completed 6 maintenance TMZ cycles (TMZ/RT / TMZ) without progression and then either were followed up by observation (group A) or continued TMZ maintenance (group B). Patient characteristics in both groups were similar (table 1), but 10 of 17 patients with IDH-mutant tumors belonged to group B, and 6 of these 10 patients were long-term survivors (OS . 48 months). Prolonged maintenance TMZ treatment results in better PFS but not OS ( figure 1A) , whereas survival did not differ between groups A and B analyzed in the group of patients with a methylated MGMT promoter (figure 1B) . In patients with an unmethylated MGMT promoter methylation status, extended TMZ treatment was associated with increased PFS (figure 1B), but there were more IDH-mutant patients (n 5 5) in this subgroup than in the subgroup of unmethylated patients who received only 6 cycles of TMZ (n 5 0) (data not shown). This is different from the preliminary analysis reported by Blumenthal et al., 13 who found TMZ beyond 6 cycles to be linked to improved PFS in patients with MGMT promoter-methylated tumors.
Induction of chemoresistance by continued exposure to TMZ itself may limit a potential benefit from extending maintenance TMZ treatment. There might be a link of a hypermutated phenotype of glioblastoma at the time of recurrence related to TMZ pre-exposure. 29 This hypermutated phenotype involves mutations in mismatch repair pathway genes, which are a pathway of acquired resistance to TMZ in vitro and in vivo. 30, 31 Moreover, a hypermutated phenotype of gliomas may result in progression to Table 4 Multivariate analysis, mutually adjusted for all factors examined in this a more malignant tumor phenotype at the time of recurrence. 32 In Germany and other European countries, extended TMZ maintenance is probably most often considered for patients with residual tumor after 6 cycles of TMZ maintenance. This was reflected by the higher number of such patients in group B (35.6% vs 52.4%, p 5 0.114) (table 1). However, in these patients, no differences in PFS or OS were observed (table 2 and figure 1, C and D) . Multivariate analysis confirmed KPS at the time of diagnosis, MGMT promoter methylation status, IDH mutation status, and residual tumor burden after 6 cycles of TMZ to be associated with survival (table 4), but not age or extent of resection, both associated with survival in the univariate analysis (table 3) .
Limitations of this study include its uncontrolled nature, retrospective analysis albeit of prospectively assembled data, and small sample size at least for subgroups. There may have been bias toward prolonging treatment in symptomatic patients thought to be at risk of early progression or in patients in whom there was uncertainty as to whether there was progression or not. However, we conclude that any potential beneficial effect of prolonging maintenance TMZ would be so small that the patient numbers required to demonstrate this superiority in a randomized fashion would be excessive.
This study indicates that in this patient cohort of the GGN, neither PFS nor OS of patients with newly diagnosed glioblastoma was superior when patients received .6 cycles of maintenance TMZ. These data may not support the practice of extending maintenance TMZ chemotherapy, regardless of MGMT promoter methylation status or residual tumor after 6 cycles.
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